 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Horizon Therapeutics Public Limited Company (HZNP), a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally.
Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
The company's primary care marketed medicines comprise PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; VIMOVO for the relief of signs and symptoms of OA, RA, and AS and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and MIGERGOT, a therapy to abort or prevent vascular headaches, such as migraines and migraine variants.
It has collaboration agreements with Alliance for Lupus Research, Syneos Health, Inc., and HemoShear Therapeutics, LLC.
The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019.
Horizon Therapeutics Public Limited Company reported 2nd Quarter June 2020 earnings of $0.43 per share on revenue of $462.8 million. The consensus earnings estimate was $0.40 per share on revenue of $301.3 million. Revenue grew 44.3% on a year-over-year basis.
The company said it expects 2020 revenue of $1.85 billion to $1.90 billion. The company's previous guidance was revenue of $1.40 billion to $1.45 billion and the current consensus estimate is revenue of $1.67 billion for the year ending December 31, 2020.
The company recently boosted its number of shares sold from its new rare thyriod eye disease drug, Tepezza. This increase in shares sold should push share prices higher to move out of its "bullish flag" formation.
Entry Point: $72.50
Trading Range: $23.81 - $78.93
Stop Loss: $68.85
Target Price: $79.75
HZNP closed at $80.00
